Why the study?
Does prospective statin administration prevent LVEF declines 2 years after doxorubicin treatment in patients with breast cancer and lymphoma?
Does prospective statin administration prevent LVEF declines 2 years after doxorubicin treatment in patients with breast cancer and lymphoma?
Prospective statin therapy does not prevent declines in left ventricular ejection fraction at 2 years in patients receiving doxorubicin for breast cancer or lymphoma.
Answers are grounded in this paper and cite their sources.
Statin use should not yet be considered for LVEF preservation after doxorubicin; leaves open whether RCTs would demonstrate benefit.
In patients with breast cancer and lymphoma with no existing indication for statin therapy, prospective statin administration did not affect LVEF declines 2 years after doxorubicin. (Funded by the National Institutes of Health; ClinicalTrials.gov number, NCT01988571.).
No takes yet. Share an insight, caveat, or question.
Hundley et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: